Radiopharmaceuticals and the Applications in Cancer Theranostics

Dear Colleagues,

The use of radiopharmaceuticals as specialized drugs that combine diagnostic imaging and targeted therapy, known as theranostics, allows for the precise detection and treatment of cancers. Among their most promising applications are FDA-approved therapies for neuroendocrine tumors or prostate cancer, representing an important step toward personalized medicine. On the one hand, diagnosis involves accurate detection of patient stratification and treatment planning. On the other hand, therapy requires a particular level of selectivity to maximize efficacy. Consequently, combining both processes that act synergistically or additively is a major challenge in current science.

This Special Issue welcomes review articles, original research articles, short communications, and perspectives on the following aspects:

• Evolution of radiopharmaceuticals for cancer theranostics.
• New targets to develop cancer theranostics (for example, immune checkpoints, among others);
• Established and novel radionuclides for cancer theranostics;
• Current and emerging applications in cancer theranostics;
• Studies on drug-like properties, studies of new radiotheranostic agents;
• Regulatory requirements and other considerations for the development of new radiotheranostics;
• Artificial Intelligence approaches to improve theranostics treatments (for example, tumor segmentation, dosimetry, and treatment optimization, among others).

Prof. Dr. Hugo Cerecetto
Dr. María Alejandra Dagrosa
Dr. María Fernanda García
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.